NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2016
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Macular degeneration; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms NEWTON
- 07 Dec 2016 Status changed from active, no longer recruiting to completed.
- 17 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 17 Feb 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.